<DOC>
	<DOCNO>NCT00195793</DOCNO>
	<brief_summary>The objective study evaluate effect add Tricor 145 mg daily atorvastatin 20 mg CHD lipid laboratory parameter .</brief_summary>
	<brief_title>A 16 Week Comparative Study Fenofibrate Versus Ezetimibe Add-on Therapy Atorvastatin</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Subject &gt; = 18 year age , race , gender . Subjects must follow fast parameter : LDLC &gt; 100 mg/dL &lt; 190 mg/dL . TG level &gt; = 175 mg/dL &lt; 1000 mg/dL . HDLC &lt; 40 mg/dL ( men ) &lt; 50 mg/dL ( woman ) . Subjects must one following : Treated untreated hypertension define blood pressure ( BP ) 130 mmHg &gt; = 85 mmHg ( systolic / diastolic ) . Waist circumference &gt; 88 cm ( 35 inch ) woman &gt; 102 cm ( 40 inch ) men . Fasting glucose define &gt; = 100 mg/dL &lt; = 125 mg/dL . Subject , opinion investigator , life expectancy great 6 month . Female subject must negative pregnancy test prior study enrollment . Female subject child bear potential must agree practice effective barrier method birth control duration study . Subject must willing observe Step I Diet recommend NCEP throughout study . Subject must willing participate study complete followup assessment . Subject know hypersensitivity fenofibrate , ezetimibe , atorvastatin Subject previously enrol study . Subject use investigational drug within 30 day study entry . Subject diagnose Type I Type II Diabetes Mellitus currently treat antidiabetic medication , fast glucose &gt; = 126 mg/dL . Subject history pancreatitis cholelithiasis history gastric duodenal ulcer within 3 month study entry . Subject hematologic , digestive , central nervous system disorder include cerebrovascular disease degenerative disease would limit study evaluation participation . Subject myocardial infarction , coronary bypass surgery , angioplasty within 6 month study entry . Subject unstable severe peripheral artery disease within 3 month study entry . Subject unstable angina pectoris uncontrolled cardiac arrhythmia . Subject congestive heart failure ( CHF ) define NYHA Class III IV Subject coagulopathy ( PT PTT &gt; 1.25 time control ) . Subject know impairment renal function ( serum creatinine &gt; 1.5 mg/dL ) , dysproteinemia , nephroticrange proteinuria , renal disease . Subject active chronic hepatobiliary hepatic disease ( subject AST ALT &gt; 2 time upper limit central laboratory reference range ) . Subject pregnant lactating . Subject receive hormonal therapy . Subject known history thyroid disease endocrine abnormality . Subject history diagnose hereditary acquire myopathy . Subject know HIV positive . Subject history mental instability , drug alcohol ( define great 14 drink per week ) abuse , subject treat severe psychiatric illness , , opinion investigator , may interfere optimal participation study . Subject receive solid organ transplant . Subject clinically significant , unstable , uncontrolled disease could adversely affect study participation . Subject unwilling unable consent enter study . Subject , opinion investigator , unable comply requirement study protocol unsuitable study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>fenofibrate</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>atorvastatin</keyword>
</DOC>